ZANTAC 75 Drug Patent Profile

Which patents cover Zantac 75, and when can generic versions of Zantac 75 launch?

Zantac 75 is a drug marketed by Chattem Sanofi and is included in two NDAs.

The generic ingredient in ZANTAC 75 is ranitidine hydrochloride. There is one drug master file entry for this compound. Seven suppliers are listed for this compound. Additional details are available on the ranitidine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zantac 75

A generic version of ZANTAC 75 was approved as ranitidine hydrochloride by SANDOZ on August 29^th, 1997.

Summary for ZANTAC 75

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	22
Patent Applications:	4
What excipients (inactive ingredients) are in ZANTAC 75?	ZANTAC 75 excipients list
DailyMed Link:	ZANTAC 75 at DailyMed

Recent Clinical Trials for ZANTAC 75

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Food and Drug Administration (FDA)	Phase 1
Spaulding Clinical Research LLC	Phase 1
Nova Scotia Health Authority	Phase 4

See all ZANTAC 75 clinical trials

US Patents and Regulatory Information for ZANTAC 75

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chattem Sanofi	ZANTAC 75	ranitidine hydrochloride	TABLET, EFFERVESCENT;ORAL	020745-001	Feb 26, 1998		DISCN	Yes	No
Chattem Sanofi	ZANTAC 75	ranitidine hydrochloride	TABLET;ORAL	020520-001	Dec 19, 1995		DISCN	Yes	No

Expired US Patents for ZANTAC 75

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Chattem Sanofi	ZANTAC 75	ranitidine hydrochloride	TABLET;ORAL	020520-001	Dec 19, 1995	4,128,658

International Patents for ZANTAC 75

See the table below for patents covering ZANTAC 75 around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	375931
Austria	381937
Austria	A322880

Market Dynamics and Financial Trajectory for ZANTAC 75

Last updated: February 10, 2026

Summary

ZANTAC 75 (ranitidine) was a widely prescribed over-the-counter and prescription medication used to treat acid reflux, ulcers, and related gastrointestinal conditions. Its market presence declined sharply following FDA's recall in April 2020 due to contamination concerns involving N-nitrosodimethylamine (NDMA), a probable carcinogen. Since then, the drug’s market dynamics have shifted from stable growth to market exit, with significant financial implications for manufacturers.

Market Overview

• Pre-Recall Market Share: ZANTAC (ranitidine) held a substantial share of the upper GI segment, with sales in the US reaching approximately $214 million in 2019 [1].
• Sales Decline Post-Recall: FDA's recall issued on April 1, 2020, led to a rapid sales decline, with pharmaceutical companies discontinuing distribution.
• Market Segmentation: Prior to recall, marketed as OTC and prescription, often substituting for omeprazole or esomeprazole in certain patient groups.

Impact of Recall and Regulatory Actions

• Recall Scope: Voluntary recalls by multiple companies, including Sanofi, after detection of NDMA contamination in ranitidine products.
• Regulatory Stance: FDA advised against use of ranitidine products, citing potential health risks.
• Product Discontinuation: Pharmacovigilance concerns led to market withdrawal; few companies reintroduced the drug.

Financial Trajectory

Period	Revenue (USD millions)	Market Share	Remarks
2018-2019	~$214	~10% of OTC GI market	Peak following extensive marketing efforts
Q1 2020 (Pre-Recall)	~$20	Declining	Anticipated decline due to upcoming regulatory actions
Q2 2020 onward	<$1	Marginal	Post-recall, market virtually ceased; sales fell below detection levels

• Market Exit: By Q3 2020, most manufacturers withdrew ZANTAC products from shelves.
• Compensation and Litigation: Ongoing lawsuits relating to NDMA exposure damage potential; financial liabilities effective post-2020.

Future Outlook

• Market Re-entry Likelihood: Low; the FDA has not approved renewed marketing of ranitidine. Development of alternative H2 receptor antagonists (e.g., famotidine) continues.
• Patent and Exclusivity: No recent patents for ZANTAC; existing patents expired well before 2020, eliminating exclusivity.
• Generic Market: No significant generic re-commercialization is expected given regulatory barriers and liability issues.

Competitive Landscape Post-ZANTAC

• Alternatives: Omeprazole, esomeprazole, famotidine assume dominance.
• Market Share Evolution: Proton pump inhibitors (PPIs) gained market dominance; H2 antagonists partially retained for specific indications.
• Emerging Therapies: Novel acid suppression drugs and biologics under clinical evaluation.

Key Takeaways

• ZANTAC 75 had a dominant market position until regulatory and safety concerns caused a near-total market exit.
• The 2020 NDMA contamination scare effectively ended ZANTAC's commercial viability.
• The shift to PPIs and alternative therapies is sustainable, with no reinstatement predicted.
• Ongoing litigation and liability issues may influence residual and future market actions.
• The market has realigned towards newer, safer GERD treatments, diminishing the role of historical drugs like ZANTAC.

FAQs

1. When was ZANTAC 75 withdrawn from the market?

   • The FDA issued a recall in April 2020; most products were withdrawn by mid-2020.

2. Can ZANTAC be reintroduced legally?

   • Currently, the FDA has not approved a reintroduction of ranitidine products.

3. What are the main alternatives to ZANTAC?

   • Proton pump inhibitors such as omeprazole and esomeprazole, and other H2 antagonists like famotidine.

4. How did the recall impact the pharmaceutical companies involved?

   • It led to revenue loss, product discontinuation, and ongoing litigation expenses.

5. What is the potential for future litigation related to ZANTAC?

   • Legal actions citing NDMA exposure continue, potentially resulting in significant liabilities.

---

Sources

[1] IQVIA, 2019 Pharmaceutical Market Data.